IRVINE, CA -- (Marketwire) -- 12/30/08 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced that the nationally syndicated TV show "The Doctors" is scheduled to broadcast a root canal procedure performed using BIOLASE's Endolase(TM) RFT Root Canal Therapy System on Thursday, January 8.
The procedure, videotaped on November 10, was performed live by Dr. Darrell Chun, a leading Waterlase Dentist. The entire root canal procedure, performed using a Waterlase® MD YSGG laser system and Endolase(TM) radial firing laser tips, was completed without numbing this dental-phobic patient, who had previously experienced a very painful, traditional root canal.
BIOLASE Chief Executive Officer Jake St. Philip said, "This is great exposure for our dental laser systems and provides an opportunity for viewers to see firsthand what a difference this advancement can do for a notoriously painful dental experience. We believe laser dentistry is becoming an emerging standard, enhancing outcomes and providing a more comfortable patient experience."
In March of this year, the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance of its Waterlase MD with RFT endoTips for root canal disinfection after endodontic instrumentation, making BIOLASE the first company to receive clearances that allow dentists to treat infected, painful toothaches with advanced laser technology.
For local broadcast time and channel, visit "The Doctors" website at http://www.thedoctorstv.com/main/local_listings.
"The Doctors" with 1.2 million viewers is a spin-off of the "Dr. Phil Show" and covers the entire spectrum of health and medical issues with an emphasis on the very latest news, trends and technologies in healthcare.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
David M. Mulder
Chief Financial Officer
BIOLASE Technology, Inc.
Allen & Caron